StockNews.com cut shares of DaVita (NYSE:DVA – Free Report) from a buy rating to a hold rating in a research note issued to investors on Friday morning.
Several other research firms also recently commented on DVA. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Finally, Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $166.33.
Check Out Our Latest Stock Analysis on DVA
DaVita Stock Down 0.5 %
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Research analysts anticipate that DaVita will post 10.76 EPS for the current fiscal year.
Hedge Funds Weigh In On DaVita
A number of hedge funds have recently modified their holdings of DVA. Copia Wealth Management purchased a new position in shares of DaVita during the 4th quarter worth $30,000. SBI Securities Co. Ltd. purchased a new position in DaVita during the 4th quarter valued at about $41,000. Coppell Advisory Solutions LLC boosted its holdings in DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after acquiring an additional 100 shares during the period. Canada Post Corp Registered Pension Plan purchased a new position in DaVita during the 4th quarter valued at about $55,000. Finally, Quarry LP purchased a new position in DaVita during the 3rd quarter valued at about $60,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Stories
- Five stocks we like better than DaVita
- What is a Secondary Public Offering? What Investors Need to Know
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Growth Stocks: What They Are, Examples and How to Invest
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.